Cargando…
Clinical Escherichia coli: From Biofilm Formation to New Antibiofilm Strategies
Escherichia coli is one of the species most frequently involved in biofilm-related diseases, being especially important in urinary tract infections, causing relapses or chronic infections. Compared to their planktonic analogues, biofilms confer to the bacteria the capacity to be up to 1000-fold more...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229135/ https://www.ncbi.nlm.nih.gov/pubmed/35744621 http://dx.doi.org/10.3390/microorganisms10061103 |
_version_ | 1784734665338257408 |
---|---|
author | Ballén, Victoria Cepas, Virginio Ratia, Carlos Gabasa, Yaiza Soto, Sara M. |
author_facet | Ballén, Victoria Cepas, Virginio Ratia, Carlos Gabasa, Yaiza Soto, Sara M. |
author_sort | Ballén, Victoria |
collection | PubMed |
description | Escherichia coli is one of the species most frequently involved in biofilm-related diseases, being especially important in urinary tract infections, causing relapses or chronic infections. Compared to their planktonic analogues, biofilms confer to the bacteria the capacity to be up to 1000-fold more resistant to antibiotics and to evade the action of the host’s immune system. For this reason, biofilm-related infections are very difficult to treat. To develop new strategies against biofilms, it is important to know the mechanisms involved in their formation. In this review, the different steps of biofilm formation in E. coli, the mechanisms of tolerance to antimicrobials and new compounds and strategies to combat biofilms are discussed. |
format | Online Article Text |
id | pubmed-9229135 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92291352022-06-25 Clinical Escherichia coli: From Biofilm Formation to New Antibiofilm Strategies Ballén, Victoria Cepas, Virginio Ratia, Carlos Gabasa, Yaiza Soto, Sara M. Microorganisms Review Escherichia coli is one of the species most frequently involved in biofilm-related diseases, being especially important in urinary tract infections, causing relapses or chronic infections. Compared to their planktonic analogues, biofilms confer to the bacteria the capacity to be up to 1000-fold more resistant to antibiotics and to evade the action of the host’s immune system. For this reason, biofilm-related infections are very difficult to treat. To develop new strategies against biofilms, it is important to know the mechanisms involved in their formation. In this review, the different steps of biofilm formation in E. coli, the mechanisms of tolerance to antimicrobials and new compounds and strategies to combat biofilms are discussed. MDPI 2022-05-26 /pmc/articles/PMC9229135/ /pubmed/35744621 http://dx.doi.org/10.3390/microorganisms10061103 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ballén, Victoria Cepas, Virginio Ratia, Carlos Gabasa, Yaiza Soto, Sara M. Clinical Escherichia coli: From Biofilm Formation to New Antibiofilm Strategies |
title | Clinical Escherichia coli: From Biofilm Formation to New Antibiofilm Strategies |
title_full | Clinical Escherichia coli: From Biofilm Formation to New Antibiofilm Strategies |
title_fullStr | Clinical Escherichia coli: From Biofilm Formation to New Antibiofilm Strategies |
title_full_unstemmed | Clinical Escherichia coli: From Biofilm Formation to New Antibiofilm Strategies |
title_short | Clinical Escherichia coli: From Biofilm Formation to New Antibiofilm Strategies |
title_sort | clinical escherichia coli: from biofilm formation to new antibiofilm strategies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229135/ https://www.ncbi.nlm.nih.gov/pubmed/35744621 http://dx.doi.org/10.3390/microorganisms10061103 |
work_keys_str_mv | AT ballenvictoria clinicalescherichiacolifrombiofilmformationtonewantibiofilmstrategies AT cepasvirginio clinicalescherichiacolifrombiofilmformationtonewantibiofilmstrategies AT ratiacarlos clinicalescherichiacolifrombiofilmformationtonewantibiofilmstrategies AT gabasayaiza clinicalescherichiacolifrombiofilmformationtonewantibiofilmstrategies AT sotosaram clinicalescherichiacolifrombiofilmformationtonewantibiofilmstrategies |